for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Puretech Health PLC

PRTC.L

Latest Trade

294.00GBp

Change

1.00(+0.34%)

Volume

88,108

Today's Range

288.00

 - 

300.00

52 Week Range

155.50

 - 

335.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
293.00
Open
289.00
Volume
88,108
3M AVG Volume
3.43
Today's High
300.00
Today's Low
288.00
52 Week High
335.00
52 Week Low
155.50
Shares Out (MIL)
285.37
Market Cap (MIL)
833.57
Forward P/E
--
Dividend (Yield %)
--

Next Event

PureTech Health PLC Annual Shareholders Meeting

Latest Developments

More

Puretech Health Says Akili's New ADHD Trial Met Primary Endpoint

PureTech Announces Follica Positive Androgenetic Alopecia Study

Puretech Health Says Akili Meets Primary Endpoint In Mdd Clinical Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Puretech Health PLC

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.

Industry

Biotechnology & Drugs

Contact Info

501 Boylston St Ste 6102

+1.617.4822333

http://puretechhealth.com/

Executive Leadership

Christopher A. Viehbacher

Interim Non-Executive Chairman of the Board

Bharatt M. Chowrira

President, Chief of Business and Strategy

Daphne Zohar

Chief Executive Officer, Co-Founder, Director

Robert Langer

Co-Founder, Non-Executive Director

Bennett M. Shapiro

Co-Founder, Non-Executive Director

Key Stats

1.00 mean rating - 3 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
54.07
Price To Book (MRQ)
3.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
18.46
LT Debt To Equity (MRQ)
16.02
Return on Investment (TTM)
-17.99
Return on Equity (TTM)
-13.04

Latest News

Latest News

BRIEF-Puretech Says ‍Follica Rain Pivotal Study Expected To Commence Following Completion Of Ongoing Optimisation Study​

* FOLLICA RAIN PIVOTAL STUDY IS EXPECTED TO COMMENCE FOLLOWING COMPLETION OF AN ONGOING OPTIMISATION STUDY

BRIEF-Puretech Says Lilly To Invest $5M In PureTech's Entrega

* PURETECH'S ENTREGA TO RECEIVE $5 MILLION INVESTMENT FROM LILLY TO ADVANCE PROPRIETARY ORAL DELIVERY TECHNOLOGY FOR PEPTIDES Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-Puretech Health Says Restorbio Files IPO Registration Statement​

* PREVIOUSLY CONFIDENTIALLY SUBMITTED DRAFT REGISTRATION STATEMENT WITH US SEC RELATING TO PROPOSED IPO OF ITS COMMON STOCK

BRIEF-PureTech affiliate Gelesis reports weight loss in study

* gelesis reports significant weight loss with excellent safety profile in pivotal study with gelesis100

BRIEF-PureTech initiates phase 2b inhibitors study in respiratory tract infections

* Announces initiation of phase 2b mtorc1 inhibitors study in elderly patients at increased risk of respiratory tract infections

BRIEF-PureTech Health launches new immuno-oncology programme

* Advances new programme targeting immunosuppressive gamma delta t cells and related mechanisms

BRIEF-PureTech Health's Akili announces pilot study results

* Results from project EVO pilot study showed improved cognitive control in children with sensory processing dysfunction, attentional deficits Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Puretech Health appoints Bharatt Chowrira as president and chief of business and strategy

* Appoints Bharatt Chowrira, PH.D., J.D., as president and chief of business and strategy Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up